Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 31 (1-2) , 267-268
- https://doi.org/10.1016/s0041-1345(98)01529-2
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1Transplantation, 1999
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1Transplantation, 1997
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- Monoclonal Antibody AdministrationClinical Pharmacokinetics, 1992
- A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL ANTIBODY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1991
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- A humanized antibody that binds to the interleukin 2 receptor.Proceedings of the National Academy of Sciences, 1989